PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS
Abstract
Premises and purpose of the study. Venous thromboembolism (VTE) is an important cause of morbidity and mortality among patients with cancer. According to recent guidelines its initial treatment may involve low-molecular-weight heparin (LMWH) or a direct oral anticoagulant (DOAC), as well as for long-term anticoagulation. Therefore, we conducted this Survey aimed at knowing aspects of the treatment of VTE in patients with cancer in the Campania Region. Materials and methods. In December 2023, a questionnaire (Q) with 14 questions relating to the treatment of VTE in patients (pts) with cancer was sent to FADOI members in Campania. 55 pratictioners from 40 Internal Medicine Wards of Campania. Results. The percentage of pts with cancer admitted in Internal Medicine ward presenting VTE: <25% (69%), 25-50%(31%). All pts with cancer and VTE begin anticoagulant treatment during hospidalitation. Its initial treatment is based on LMWH: all pts (29%), a small part 9%, most (62%), while on DOAC: all pts (11%), none (1.8%), a small part (52.7%), most 34.5%. Comorbidities in the 70% of the cases influence the choice of treatment. Mortality of this pts: <20% (42%), 20-40%(22%),41-60%(4%), unknown (32%). In the discharge letter of pts with cancer and VTE, LMWH are prescribed: <25% (45.5%), 25-50% (31%), 51-75% (9%), >75% (14.5%), while DOAC: <25% (11%), 25-50% (31%), 51-75% (16%), 75% (42%). Conclusions. In Internal Medicine Wards of Campania LMWH is preferred over DOAC in initial treatment of VTE in pts with camcer, while for long-term anticoagulation DOAC is preferred over LMWH.
Related
- Proactive Opportunities for Advance Care Planning (PRO-ACP): improving advance care planning completion among hospitalised internal medicine patients with life-limiting illness.
- Academic treatment optimization studies in oncology and internal medicine: a risk- and burden-adapted regulatory framework for the European Union.
- Recalculated HOMA-IR and Recorded Blood Pressure Changes in Treated Internal Medicine Patients: An Exploratory Retrospective Study
- A Pilot Real-life Study Opioid Induced Constipation in Neoplastic Patients Admitted to Internal Medicine Ward. Outcome of Naldemedine Therapy According to Available Guidelines
- Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study
BibTeX
@article{marrone2026po156,
title = {{PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS}},
author = {Emiliana Marrone},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/972},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS
AU - Emiliana Marrone
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/972
AB - Premises and purpose of the study. Venous thromboembolism (VTE) is an important cause of morbidity and mortality among patients with cancer. According to recent guidelines its initial treatment may involve low-molecular-weight heparin (LMWH) or a direct oral anticoagulant (DOAC), as well as for long-term anticoagulation. Therefore, we conducted this Survey aimed at knowing aspects of the treatment of VTE in patients with cancer in the Campania Region. Materials and methods. In December 2023, a questionnaire (Q) with 14 questions relating to the treatment of VTE in patients (pts) with cancer was sent to FADOI members in Campania. 55 pratictioners from 40 Internal Medicine Wards of Campania. Results. The percentage of pts with cancer admitted in Internal Medicine ward presenting VTE: <25% (69%), 25-50%(31%). All pts with cancer and VTE begin anticoagulant treatment during hospidalitation. Its initial treatment is based on LMWH: all pts (29%), a small part 9%, most (62%), while on DOAC: all pts (11%), none (1.8%), a small part (52.7%), most 34.5%. Comorbidities in the 70% of the cases influence the choice of treatment. Mortality of this pts: <20% (42%), 20-40%(22%),41-60%(4%), unknown (32%). In the discharge letter of pts with cancer and VTE, LMWH are prescribed: <25% (45.5%), 25-50% (31%), 51-75% (9%), >75% (14.5%), while DOAC: <25% (11%), 25-50% (31%), 51-75% (16%), 75% (42%). Conclusions. In Internal Medicine Wards of Campania LMWH is preferred over DOAC in initial treatment of VTE in pts with camcer, while for long-term anticoagulation DOAC is preferred over LMWH.
SN - 2785-5309
ER -